Abstract
Background Cerebral Small Vessel Disease (cSVD) of ischemic type, either sporadic or genetic, as Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL), can impact the quality of daily life on various cognitive, motor, emotional or behavioral aspects. No instrument has been developed to measure these outcomes from the patient’s perspective. We thus aimed to develop and validate a patient-reported questionnaire.
Methods In a development study, 79 items were generated by consensus between patients, family representatives and cSVD experts. A first sample of patients allowed assessing the feasibility (missing data, floor and ceiling effect, acceptability), internal consistency, and dimensionality of a first set of items. Thereafter, in a validation study, we tested a reduced version of the item set in a larger sample to assess the feasibility, internal consistency, dimensionality, test-retest reliability, concurrent validity, and sensitivity to change.
Results The scale was developed in 44 cSVD patients and validated in a second sample of 89 individuals (including 43 patients with CADASIL and 46 with another cSVD). The final CADASIL Patient-Reported Outcome (CADA-PRO) scale comprised 18 items covering four categories of consequences (depression/anxiety, attention/executive functions, motor, daily activities) of the disease. The proportion of missing data was low, no item displayed major floor or ceiling effect. Both the internal consistency and test-retest reliability were good (Cronbach alpha = 0.95, intraclass correlation coefficient = 0.88). In patients with CADASIL, CADA-PRO scores correlated with the modified Rankin scale, Starkstein Apathy Scale (SAS), Hospital Anxiety and Depression scale (HAD), and Trail Making Test times. In patients with other cSVDs, CADA-PRO correlated only with HAD and SAS.
Conclusion The CADA-PRO is an innovative instrument for measuring patient-reported outcomes in future cSVD trials. Full validation was obtained for its use in CADASIL patients, but further improvement is needed for its application in other cSVDs.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was mainly supported by the ANR grant RHU TRT—cSVD (ANR:16-RHUS-0004) and a grant from H2020 EJPRD - CADANHIS. The study was also done with the help of the Association ARNEVA (Association de Recherche en Neurologie Vasculaire).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Informed consent was obtained from each subject or a close relative if necessary. Data were collected through the SMACS study, which was approved by the Comité de Protection des Personnes Ile de France IV (2019-A01892-55).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Anonymized data not published within this article will be made available upon request from any qualified investigator.
Non-standard Abbreviations and Acronyms
- CADASIL
- cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy
- cSVD
- cerebral Small Vessel Disease
- EF
- Executive Functions
- EFA
- Exploratory Factor Analysis
- FCSRT
- Free and Cued Selective Reminding Test
- HAD
- Hospital Anxiety and Depression scale
- MIRT
- Confirmatory Multidimensional Item Response Theory
- mRS
- modified Rankin scale
- PGIC
- Patient Global Impression of Change
- SAS
- Starkstein Apathy Scale
- SSPB - 4
- Short Physical Performance Battery (4 items)
- TMT
- Trail Making Test
- VADAS-Cog
- Vascular Dementia Assessment Scale cognitive subscale
- SDMT
- Symbol-Digit Modalities Test
- WCST
- Wisconsin Card Sorting Test
- WMS-III
- Weschler Memory Scale 3rd revision
